People need to remember the excellent structure of the business model & this is really just ironing out the flaws or difficulties discovered over time. Largely being too locked into the very early stage screening & discovery has proven difficult in that it's not taking it far enough - big pharma don't want to take up very early stage work they want candidates at proof of concept & that have been able to show activity in-vivo, efficacy, PK, toxicity - basically candidates that are ready into step into a Phase I trial against a specific target.
The business model is excellent but this new step forward is what it needs to make it work -
About Us
Phylogica is a leading peptide drug discovery company that utilises proprietary Phylomer® peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.
The Company’s libraries contain billions of distinct peptides known as Phylomer® peptides, which represent a rich source of biologically active drug leads. These natural peptides are based on expressed sequences of protein fragments that are encoded by the genes of evolutionary diverse microbes and they thus represent a new class of biological therapeutics. Phylomer® peptides display exceptional structural stability, specificity and affinity, thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies.
The quality of Phylomer® libraries has been validated through partnerships with major pharmaceutical companies that include Roche, MedImmune (worldwide biologics unit of AstraZeneca), Pfizer and Janssen Biotech (the pharmaceutical division of Johnson & Johnson).
Phylogica operates a contract drug discovery partnership business model. This drives revenue through upfront technology access fees, significant ongoing milestone payments and later royalties on successful drugs once they reach the market.
The Company has a strong and broad intellectual property portfolio around its proprietary Phylomer® peptide libraries and associated technology.
Strategy
Phylogica’s business strategy is focused on providing peptide drug discovery partnerships, based on it’s proprietary Phylomer® libraries and screening technologies, to pharmaceutical and biotechnology companies.
Phylogica’s drug discovery services are accessed through partnership deals that comprise upfront technology fees, significant ongoing milestone payments and later royalties on marketed drugs.
Partnerships are structured such that the partner company is responsible for the complex later stages of drug development and therefore the financial burden and the risks associated with drug failure. With a few partnerships in place, Phylogica is cash flow positive. Furthermore as ongoing milestone payments can begin a few months after commencing the collaboration, thus a strong asset base can be quickly established.
Adopting this business model is enabling Phylogica to become a profitable, lower risk, revenue and value creator.
PYC Price at posting:
3.7¢ Sentiment: None Disclosure: Held
(20min delay)